Summary & Overview
HCPCS C9307: Linvoseltamab-gcpt Injection, 1 mg
HCPCS Level II code C9307 denotes a 1 mg unit of linvoseltamab-gcpt, an injectable biologic used in specialty oncology/hematology care. Nationally, unit-based HCPCS drug codes like C9307 are important for billing accuracy, drug utilization tracking, and payment policy for high-cost specialty therapies administered in outpatient and infusion settings. Payers rely on these codes for claims adjudication, prior authorization workflows, and cost-management strategies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical sites of service, plus benchmarking and policy-relevant content where available. The publication covers common reimbursement and billing considerations for unit-based HCPCS drug codes, implications for site-of-care payment differences, and the role of such codes in utilization review and prior authorization processes. Where input data is incomplete, the text notes unavailable elements rather than inferring specifics.
This summary is intended for billing managers, revenue cycle leaders, and policy analysts seeking a national perspective on coding and billing implications for linvoseltamab-gcpt administered as an injectable specialty therapy.
Billing Code Overview
HCPCS Level II code C9307 describes Injection, linvoseltamab-gcpt, 1 mg. This code represents a single milligram unit of linvoseltamab-gcpt, a biologic injectable formulation used in specialty oncology or hematology treatment regimens.
Service Type: Drug administration — injectable biologic product
Typical Site of Service: Infusion center, outpatient clinic, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with relapsed or refractory multiple myeloma presents to an outpatient oncology infusion center for treatment with linvoseltamab-gcpt. The patient has disease progression after prior lines of therapy and meets criteria for a bispecific T-cell engager therapy. Pre-infusion evaluation includes confirmation of diagnosis, baseline labs (CBC, CMP), assessment for active infection, review of prior neurologic history, and discussion of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) risk. On the day of service, the oncology RN performs medication verification, IV access placement, and administers premedications per protocol. The drug is prepared by pharmacy as a preservative-free injectable formulation labeled as linvoseltamab-gcpt and administered intravenously in milligram doses billed using C9307 per 1 mg units. Post-infusion monitoring occurs in the infusion center for vital signs, neurologic checks, and management of adverse events; the patient may require extended observation or transfer to hospital if severe CRS or neurotoxicity develops. Typical sites of service include outpatient oncology infusion centers, hospital outpatient departments, and specialty ambulatory infusion clinics. Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage adjudication and prior authorization workflows.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|